Solid Tumor Testing in United States Trends and Forecast
The future of the solid tumor testing market in United States looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1641.7 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The solid tumor testing market in United States is also forecasted to witness strong growth over the forecast period. The major drivers for this market are an increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.
• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.
Emerging Trends in the Solid Tumor Testing Market in United States
The solid tumor testing market in the United States is expanding tremendously due to progress in technology, research, and the healthcare sector. The market has several trends, some of which are improving cancer detection and treatment through methods like non-invasive testing, artificial intelligence, and advancements in personalized medicine. These trends not only aid in enabling but also promise better patient outcomes and more effective cancer control techniques.
• Liquid Biopsy Advancements: Liquid biopsy is rapidly becoming one of the most significant trends in the solid tumor testing market. This non-invasive method has the potential to replace tissue biopsies by using blood samples to detect genetic mutations and other cancer biomarkers. Liquid biopsy allows for early-stage cancer diagnosis and continuous monitoring of tumor progression, enabling real-time treatment adjustments. Liquid biopsies are expected to become commonplace in oncology due to new technologies that allow for straightforward, precise procedures while reducing the need for invasive actions.
• AI-Assisted Imaging and Diagnostics: The integration of AI into the imaging of solid tumors is redefining solid tumor testing. Radiologists using CT, MRI, and PET scans often have their work remapped by algorithms created by AI. AI’s integration into medical processes reduces the chances of misdiagnoses by aiding in the earlier and more precise detection of tumors. As AI shifts toward the diagnostic realm, this change is benefiting the United States by improving diagnostic workflows, accelerating the pace, and offering higher clinical benefits.
• Personalized Medicine with Treatment Adaptation and Tumor Genetics: The introduction of personalized medicine, aided by genomic examination, is changing the approach to cancer treatment in the United States. Genomic testing looks for distinct mutations within tumors to prescribe the right treatment to the patient. This emerging trend offers a more realistic approach to treating cancer, targeting the specific genetic composition of both the tumor and the patient. The availability of genomic testing is making results more efficient for patients and doctors while avoiding side effects from treatments.
• AI-Powered Pathology: AI is being used in pathology to improve the analysis of tissue samples by estimating the tumor type, stage, and molecular features. Through automation, such as image analysis, AI in pathology enhances precision while reducing human error. Additionally, AI systems can recognize complex patterns within large amounts of data that help guide prognosis and treatment. Sophisticated AI pathology devices are expected to become standard investigative tools for American oncologists as these devices continue to advance, along with their importance in accurate diagnosis.
• Integration of Companion Diagnostics: The integration of companion diagnostics is steadily increasing in solid tumor testing. Companion diagnostics are tests that identify subsets of patients most likely to benefit from specific therapies, especially targeted and immunotherapies. Companion diagnostics target particular cancers to ensure patients receive the most effective treatment, improving their chances of a favorable outcome. As cancer therapies become more sophisticated, there is a noticeable increase in the use of companion diagnostics, making them an integral part of personalized cancer care in the United States.
In the United States, trends within the solid tumor testing market are expected to improve accuracy and precision in cancer diagnosis, ultimately making intervention less painful. Cancer is getting easier to detect and treat due to innovations like genomic analysis, artificial intelligence, and liquid biopsies. These trends are pushing changes in technology and efficiency in cancer care, benefiting more patients across the nation.
Recent Developments in the Solid Tumor Testing Market in United States
The oncology sector in the United States has grown tremendously in the past couple of years, with many new changes emerging within solid tumor testing. Expansion in these markets is being fueled by modern technology, new research, and the increasing adoption of personalized medicine. The introduction of liquid biopsies, artificial intelligence, and genomic profiling marks a new era in cancer detection and intervention, offering less invasive methods and more effective treatment options.
• Liquid Biopsy for Early Cancer Detection: There has been significant progress in liquid biopsy, a method used for cancer detection through blood sample analysis. It is considered one of the most innovative developments in the solid tumor testing market. Unlike conventional methods that require tissue biopsies, liquid biopsies help identify cancer-associated biomarkers without the need for tissue removal. This approach is especially advantageous for detecting hard-to-biopsy tumors, as it provides a way to monitor these masses without additional procedures. The increased adoption of liquid biopsy in clinical practice has led to improved accuracy and speed in cancer diagnostics.
• Artificial Intelligence in Radiology: The emergence of artificial intelligence (AI) in radiology promises significant improvements in solid tumor testing. AI algorithms are proving to be useful for diagnostic imaging specialists working with CT, MRI, and PET scans. AI helps detect tumors that may otherwise go undetected and speeds up the analysis of scans, allowing for more timely diagnosis and treatment. As AI continues to integrate further into routine processes, diagnostic imaging specialists can work more efficiently, resulting in earlier detection and treatment of cancer patients, which improves patient outcomes.
• Expansion of Genomic Testing: Genomic testing is expanding rapidly as an important component of diagnosing somatic tumors and formulating treatment strategies. Genomic tests assist oncologists in therapeutic selection by identifying hereditary abnormalities within a patient’s tumor. This shift allows for a move from broad treatments to more targeted and accurate therapies. As genomic testing becomes more frequent and accessible, solid tumors are being treated with greater precision, leading to better results for patients.
• Integration of Immunotherapy in Tumor Testing: The application of the body’s immune system to treat cancer, known as immunotherapy, is a key focus in solid tumor testing. Innovations in testing are being developed to assess how well a patient responds to immunotherapy and improve treatment outcomes. By focusing on specific biomarkers that mediate the immune response, tests can now help identify patients most likely to benefit from immunotherapy. This marks a significant shift in cancer management as more patients transition to personalized medicine.
• Growing Regulatory Approvals for New Diagnostic Tools: Together with AI-powered diagnostic software, emerging technologies such as liquid biopsy tests are gaining wider acceptance in clinical settings. This is leading to higher approval rates from the FDA for tools used in solid tumor testing. Innovative testing methods continue to accelerate the availability of diagnostic solutions, which aid oncologists in detecting and treating solid tumors. These tools will ensure growth and expansion in the market as they become more accessible.
The transformation of cancer diagnosis and treatment is the latest trend within the solid tumor testing market in the United States. Innovations such as liquid biopsy, AI-driven diagnostics, and genomic profiling are creating a paradigm shift in the accessibility of cancer patients to early diagnosis and treatment, ultimately increasing patient value. These breakthroughs are promoting oncology care to become more targeted, thus bolstering innovation in personalized medicine. The evolution of these technologies will shape the future of solid tumor testing in the United States.
Strategic Growth Opportunities for Solid Tumor Testing Market in United States
The solid tumor testing market within the United States is expanding considerably due to technological advancements, increasing cancer cases, and the growing acceptance of customized medicine. Many growth opportunities are available in this market, particularly in primary applications such as liquid biopsy, AI-driven diagnostics, personalized medicine, genomics, and immunotherapy. These opportunities not only improve cancer detection but also offer advanced, effective, and less invasive patient-specific solutions. The following outlines five key growth opportunities by application.
• Liquid Biopsy for Early Detection: Liquid biopsy is emerging as a leading growth opportunity in the solid tumor testing market. It provides the possibility to analyze a patient’s blood or other bodily fluids to check for the presence of mutations and other cancer-specific markers, eliminating the need for invasive procedures like tissue biopsy. This method allows earlier detection of solid tumors, which can help with the prompt initiation of treatment. With this technique, healthcare professionals can also track tumor development in greater detail, reducing the need for operational interventions and enabling physicians to deliver enhanced and more targeted therapies for solid tumors.
• Diagnostics Powered by AI: AI is significantly impacting the diagnosis of solid tumors. AI systems incorporate imaging and diagnostic technologies that improve the efficiency of tumor detection compared to CT, MRI, and PET scans. These systems can recognize patterns that human radiologists often miss, allowing for faster diagnosis. Combining AI with diagnostics enhances workflow, reduces time spent on diagnosis, increases the speed and accuracy of intervention, and results in improved patient outcomes.
• Medicine’s Future: Genomics: The integration of genomics in personalized medicine is fueling the solid tumor testing market. Genomic testing focuses on precisely tracking genetic alterations within tumors for targeted therapy. The development of personalized medicine allows doctors to improve cancer treatment quality while reducing its negative effects. Modern genomic sequencing enables oncologists to formulate highly individualized treatment regimens based on the tumor and the patient’s genetic profile, leading to better outcomes and reduced overtreatment.
• Testing for Immunotherapy: Immunotherapy, which uses the body’s immune system to destroy cancer cells, is one of the fastest-growing segments within the solid tumor testing market. The range of patients suitable for immunotherapies is expanding, making testing for predicting patient-specific responses to these therapies increasingly important. There is significant growth potential with companion diagnostics that assess immunotherapy biomarkers. These tests help medical professionals determine suitable patients for immunotherapy, leading to more personalized and efficient cancer treatment interventions.
• Pathologist AI: The application of artificial intelligence in pathology is changing the evaluation of tumor specimens. Devices are actively used to monitor images for analysis, classify tumor types, and identify molecular features that determine prognosis and treatment methods. These advancements increase the accuracy of tumor diagnostics and minimize errors in the evaluation of complex tissue samples. Such instruments are expected to become prevalent in U.S. oncology practices as more advances are made in precision medicine. This will greatly enhance cancer treatment.
These technologies in liquid biopsy, artificial intelligence in diagnostics, genomics, immunotherapy testing, and AI in pathology are rapidly transforming the solid tumor testing market in the U.S. They improve early cancer detection, treatment personalization, and patient outcomes. As innovations develop, they are expected to foster even greater progress in the field, making solid tumor testing more precise, less invasive, and more efficient.
Solid Tumor Testing Market in United States Driver and Challenges
The solid tumor testing market in the U.S. is impacted by various technological, economic, and regulatory factors. These drivers and challenges influence the market’s growth rate, the emergence of new innovations, and the adoption of new testing technologies. Key drivers include the rising cancer cases, advancements in technology, and the growing need for bespoke medicine. On the other hand, regulatory barriers, cost issues, and healthcare availability continue to be major challenges. The analysis below outlines the most important drivers and challenges affecting the market.
The factors responsible for driving the solid tumor testing market in the United States include:
• Growth of Technology: The growth of technology, especially AI, liquid biopsy, and genomic sequencing, is one of the primary factors driving growth in the solid tumor testing market. These innovations further improve remote cancer diagnostics through non-invasive biopsies. Detecting tumors is made easier by AI-powered imaging systems, and customizing cancer treatment now depends on the genetic makeup of the patient through genomic sequencing. These technologies not only speed up diagnosis but also make treatment more specific and effective, leading to optimal results and expanding the solid tumor testing market.
• Rise in the Number of Cancer Patients: The increasing number of cancer patients in the U.S. is a key driver of this market. As the population ages and lifestyle factors contribute to more cancer cases, the demand for effective diagnostic solutions grows. Improved detection increases the chances of successful outcomes, making advanced tests such as liquid biopsies and AI diagnostics more in demand. As the need for timely detection rises, the market for solid tumor testing technologies is expected to grow positively.
• Transition to Personalized Treatment: The shift toward personalized treatment in cancer care is a major driver of the solid tumor testing market and is expected to continue expanding. This approach involves treating specific patients with specialized medicine, using genomic work-ups and tailored drug treatments to ensure maximum benefits with minimal side effects. This trend is paving the way for genomic diagnostics and targeted interventions for specific tumor mutations. As personalized medicine becomes more prevalent, demand for solid tumor testing will increase.
• Regulatory Approvals and Investment in Research: The growing number of regulatory approvals for modern diagnostic tools, including liquid biopsy tests and AI systems, is driving growth in the solid tumor testing market. The adoption of new technologies in clinical practice has been accelerated by the U.S. FDA’s endorsement of these tools. In addition, both the public and private sectors have been proactive in fostering innovations in cancer diagnostics through research and development investments. These measures are enhancing primary cancer care and providing healthcare professionals with advanced testing options.
• Expanded Healthcare Infrastructure: The ongoing development and refinement of healthcare infrastructure in the U.S. are driving the solid tumor testing market. Urban and rural-focused healthcare services ensure more patients can benefit from advanced cancer testing techniques. The increasing number of specialized oncology centers and improved patient care facilities are fueling the adoption of solid tumor testing solutions. This infrastructure growth is crucial for ensuring that technological innovations reach a broader patient population, facilitating market growth.
Challenges in the solid tumor testing market in the United States are:
• High Testing Costs: One of the challenges facing the solid tumor testing market is the high cost of liquid biopsy and genomic testing methods. These technologies are often not affordable for many patients due to the expensive equipment and specialized expertise required to perform these tests. The costs also pose a challenge to healthcare providers who wish to offer advanced diagnostics but are financially constrained. The cost barrier remains a significant obstacle to the widespread adoption of innovative testing methodologies.
• Regulatory Hurdles: Regulations are significant barriers to the adoption of new technologies for solid tumor testing. The regulations surrounding new AI-based diagnostics and liquid biopsies differ from state to state, making it difficult for providers to use these innovative technologies consistently. Clear guidelines for utilizing such technologies are needed to accelerate growth in this market area.
• Access to Advanced Testing in Rural and Underserved Areas: One of the challenges facing solid tumor testing in the U.S. is access in rural and underserved areas. While urban areas have greater access to advanced diagnostic tools, patients in rural regions often struggle to get timely and accurate tests. These patients are often low-income and face limited healthcare access and lower health insurance coverage. Addressing these issues will enhance cancer care across the U.S., making it essential to ensure timely and accurate diagnostic tools are available to everyone.
The opportunities and challenges related to solid tumor testing in the U.S. are shaping the future of cancer care. As new technologies are developed and cancer cases rise, there is a growing market for personalized medicine. At the same time, expensive testing, regulatory hurdles, and limited access remain major barriers. Overcoming these obstacles will be essential for fostering growth in the solid tumor testing market and improving cancer detection, treatment, and patient care in the country.
List of Solid Tumor Testing Market in United States Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, solid tumor testing companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10
Solid Tumor Testing Market in United States by Segment
The study includes a forecast for the solid tumor testing market in United States by type, application, and end use.
Solid Tumor Testing Market in United States by Type [Analysis by Value from 2019 to 2031]:
• Genetic Testing
• Conventional Testing
Solid Tumor Testing Market in United States by Application [Analysis by Value from 2019 to 2031]:
• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others
Solid Tumor Testing Market in United States by End Use [Analysis by Value from 2019 to 2031]:
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions
Features of the Solid Tumor Testing Market in United States
Market Size Estimates: Solid tumor testing in United States market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Solid tumor testing in United States market size by type, application, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different type, application, and end use for the solid tumor testing in United States.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing in United States.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What are the major drivers influencing the growth of the solid tumor testing market in United States?
Answer: The major drivers for this market are increase in the utilization of supplements and steroids and increase in unhealthy habits, such as smoking and alcohol consumption.
Q2. What are the major segments for solid tumor testing market in United States?
Answer: The future of the solid tumor testing market in United States looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets.
Q3. Which solid tumor testing market segment in United States will be the largest in future?
Answer: Lucintel forecasts that melanoma is expected to witness the highest growth over the forecast period due to growing incidence of skin tumors and related conditions globally.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market in United States by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), and end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Solid Tumor Testing Market in United States, Solid Tumor Testing Market in United States Size, Solid Tumor Testing Market in United States Growth, Solid Tumor Testing Market in United States Analysis, Solid Tumor Testing Market in United States Report, Solid Tumor Testing Market in United States Share, Solid Tumor Testing Market in United States Trends, Solid Tumor Testing Market in United States Forecast, Solid Tumor Testing Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.